An International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer.

Trial Profile

An International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Ganitumab (Primary) ; Exemestane; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 12 Feb 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 03 Jul 2012 Planned number of patients changed from 150 to 156 as reported by European Clinical Trials Database record.
    • 25 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top